Chronic HCV Infection: Clinical Advances and Eradication Perspectives

Chronic HCV Infection: Clinical Advances and Eradication Perspectives

Hepatitis C virus (HCV) chronic infection can determine liver fibrosis, cirrhosis and hepatocellular carcinoma, as well as several extra-hepatic manifestations (i.e., mixed cryoglobulinemia, metabolic syndrome, kidney disease, etc.). HCV infection is asymptomatic until severe stages of disease, thus...

Full description

Saved in:
Bibliographic Details
Other Authors: Liberto, Maria Carla (Editor), Marascio, Nadia (Editor)
Format: Electronic Book Chapter
Language:English
Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
Subjects:
Medicine
Epidemiology & medical statistics
HCV
rheumatic
interferon
mortality
hepatitis C virus (HCV)
phylogeny
resistance-associated substitution (RAS)
chronic hepatitis C
vibration controlled transient elastography
fibrosis
steatosis
hepatocellular carcinoma
hepatitis C
genotype 3
liver cirrhosis
pangenotypic
children
ledipasvir/sofosbuvir
real-life
sustained virological response
elimination
model
COVID-19
PWID
homeless persons
HCV eradication
direct-acting antivirals
out-of-hospital
retention in care
n/a
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis C virus (HCV) chronic infection can determine liver fibrosis, cirrhosis and hepatocellular carcinoma, as well as several extra-hepatic manifestations (i.e., mixed cryoglobulinemia, metabolic syndrome, kidney disease, etc.). HCV infection is asymptomatic until severe stages of disease, thus screening policy in the general population and in specific risk categories is necessary to allow for timely intervention. Despite a high sustained virological response by direct-acting antiviral drugs, a limited percentage of treated subject failed therapy according to resistance associated substitution carried on viral isolates and comorbidities in infected patients. Therefore, tailored therapy is required to cure HCV infection. Failure to comply with these conditions may impair success of HCV eradication expected by 2030. This Special Issue aims to discuss eradication perspectives related to therapy efficacy in patients with chronic diseases, developments in diagnostic procedures and improvements in screening policy.
Physical Description:1 electronic resource (104 p.)
ISBN:books978-3-0365-3362-9
9783036533612
9783036533629
Access:Open Access

Similar Items